-
公开(公告)号：US09499630B2
公开(公告)日：2016-11-22
申请号：US13974792
申请日：2013-08-23
发明人： Austin L. Gurney
IPC分类号： C07K7/08 , C07K7/64 , C07K14/00 , A61K38/08 , A61K38/12 , A61K38/16 , C07K16/30 , C07K14/47 , C07K14/71 , C07K16/28
CPC分类号： C07K16/30 , C07K14/4702 , C07K14/71 , C07K16/28 , C07K2317/34 , C07K2317/55 , C07K2317/76 , C07K2317/92
摘要： Novel anti-cancer agents, including, but not limited to, antibodies and other polypeptides, that bind to human frizzled receptors are provided. Novel epitopes within the human frizzled receptors which are suitable as targets for anti-cancer agents are also identified. Methods of using the agents or antibodies, such as methods of using the agents or antibodies to inhibit Wnt signaling and/or inhibit tumor growth are further provided. Screening methods are also provided.
摘要翻译： 提供了与人类卷曲受体结合的新型抗癌剂，包括但不限于抗体和其他多肽。 还鉴定了适合作为抗癌剂靶标的人类卷曲受体中的新表位。 进一步提供使用试剂或抗体的方法，例如使用该试剂或抗体抑制Wnt信号传导和/或抑制肿瘤生长的方法。 还提供筛选方法。
-
42.发明申请公开(公告)号：US20150232570A1
公开(公告)日：2015-08-20
申请号：US14429497
申请日：2013-09-20
发明人： Timothy C. Hoey , Ann M. Kapoun , Min Wang , Tzu-Ling Tang Lin , Jennifer Anne Cain , Jakob Dupont
IPC分类号： C07K16/30 , A61K45/06 , C12Q1/68 , A61K39/395
CPC分类号： C07K16/3061 , A61K39/39558 , A61K45/06 , A61K2039/505 , A61K2039/507 , C07K16/28 , C07K2317/24 , C07K2317/33 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C12Q1/6886 , C12Q2600/106 , C12Q2600/156
摘要： NOTCH1-binding antibodies and methods of using the antibodies for treating hematologic cancers are disclosed. Methods of using antibodies that bind to a non-ligand binding membrane proximal region of the extracellular domain of human NOTCH1 and methods of treating chronic lymphocytic leukemia (CLL), hairy cell leukemia, chronic myelogenous leukemia (CML), nonHodgkin lymphoma, diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), or cutaneous T-cell lymphoma (CTCL) in a subject, comprising administering a therapeutically effective amount of a NOTCH1-binding antibody to the subject are also disclosed. Methods of identifying subjects suitable for such treatment methods are further disclosed.
摘要翻译： 公开了NOTCH1结合抗体和使用该抗体治疗血液癌症的方法。 使用结合人NOTCH1细胞外结构域的非配体结合膜近端区域的抗体的方法和治疗慢性淋巴细胞白血病（CLL），毛细胞白血病，慢性骨髓性白血病（CML），非霍奇金淋巴瘤，弥漫性大B 细胞淋巴瘤（DLBCL），套细胞淋巴瘤（MCL）或皮肤T细胞淋巴瘤（CTCL），包括向受试者施用治疗有效量的NOTCH1结合抗体。 还公开了鉴定适合于这种治疗方法的受试者的方法。
-
公开(公告)号：US08945873B2
公开(公告)日：2015-02-03
申请号：US13782671
申请日：2013-03-01
发明人： Austin L. Gurney , Timothy Charles Hoey , Edward Thein Htun van der Horst , Aaron Ken Sato , Yuan Ching Liu , Maureen Fitch Bruhns , John A. Lewicki
IPC分类号： C07H21/04 , C12N7/01 , C12N5/12 , C12N15/09 , C12N15/63 , C12N15/79 , C12P21/08 , C07K16/28 , C07K16/30 , A61K39/395 , A61K45/06 , C07K16/46 , C07K16/22 , C07K14/705 , C07K14/71 , C07K14/435 , A61K39/00
CPC分类号： C07K16/22 , A61K31/337 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K2039/505 , A61N5/10 , C07H21/04 , C07K14/435 , C07K14/71 , C07K16/28 , C07K16/30 , C07K16/3046 , C07K16/462 , C07K16/464 , C07K2317/21 , C07K2317/24 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/76 , C07K2317/92 , C12N5/0693 , C12N5/12 , C12N15/63 , C12N15/79 , C12N2501/998
摘要： The present invention relates to Notch-binding agents and Notch antagonists and methods of using the agents and/or antagonists for treating diseases such as cancer. The present invention provides antibodies that specifically bind to a non-ligand binding region of the extracellular domain of one or more human Notch receptor, such as Notch2 and/or Notch3, and inhibit tumor growth. The present invention further provides methods of treating cancer, the methods comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth.
摘要翻译： 本发明涉及Notch结合剂和Notch拮抗剂以及使用这些药剂和/或拮抗剂治疗诸如癌症的疾病的方法。 本发明提供了特异性结合一种或多种人Notch受体如Notch2和/或Notch3的细胞外结构域的非配体结合区并抑制肿瘤生长的抗体。 本发明还提供了治疗癌症的方法，所述方法包括施用治疗有效量的特异性结合人Notch受体蛋白的细胞外结构域的非配体结合区的抗体并抑制肿瘤生长。
-
公开(公告)号：US08883736B2
公开(公告)日：2014-11-11
申请号：US13801198
申请日：2013-03-13
发明人： Austin Gurney
IPC分类号： A61K38/00 , C07K16/30 , C07K16/18 , A61K39/395 , A61K45/06 , C07K16/28 , C07K14/72 , A61K39/00
CPC分类号： A61K39/39558 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K14/723 , C07K16/18 , C07K16/28 , C07K16/30 , C07K2317/14 , C07K2317/21 , C07K2317/24 , C07K2317/76 , C07K2319/30
摘要： The present invention relates to compositions and methods for characterizing, diagnosing and treating cancer. In particular, the present invention identifies LGR5 as a protein over-expressed in solid tumor stem cells. The present invention further identifies an interaction between RSPO1 and LGR5 as an alternative pathway for the activation of beta-catenin signaling. In certain embodiments, the present invention provides biomolecules that disrupt functional signaling via a LGR protein, including, in certain embodiments, molecules that inhibit the interaction between one or more RSPO proteins and one or more LGR proteins, such as LGR5. In certain embodiments, the present invention provides methods of treating cancer comprising disrupting functional LGR signaling and inhibiting growth of a solid tumor comprising solid tumor stem cells.
摘要翻译： 本发明涉及用于表征，诊断和治疗癌症的组合物和方法。 特别地，本发明将LGR5鉴定为在实体瘤干细胞中过表达的蛋白质。 本发明进一步鉴定了RSPO1和LGR5之间的相互作用，作为β-连环蛋白信号传导活化的替代途径。 在某些实施方案中，本发明提供了通过LGR蛋白破坏功能性信号传导的生物分子，包括在某些实施方案中抑制一种或多种RSPO蛋白与一种或多种LGR蛋白如LGR5之间相互作用的分子。 在某些实施方案中，本发明提供了治疗癌症的方法，包括破坏功能性LGR信号并抑制包含固体肿瘤干细胞的实体瘤的生长。
-
45.发明授权公开(公告)号：US08883145B2
公开(公告)日：2014-11-11
申请号：US13501944
申请日：2010-10-18
IPC分类号： A61K39/395 , A61K38/15 , A61P9/12 , A61K45/06 , C07K16/22 , C07K14/435
CPC分类号： C07K16/18 , A61K31/138 , A61K31/166 , A61K31/341 , A61K31/401 , A61K31/4184 , A61K31/4418 , A61K31/519 , A61K31/5377 , A61K31/55 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K2039/505 , C07K16/22 , C07K16/24 , C07K2317/31 , C07K2317/56 , C07K2317/565 , C07K2317/76 , Y10S530/80 , Y10S530/86 , A61K2300/00
摘要： Methods for treating cancer comprising administering a DLL4 antagonist and one or more anti-hypertensive agents are described. Also described are pharmaceutical compositions comprising a DLL4 antagonist and one or more anti-hypertensive agents, and kits comprising the same.
摘要翻译： 描述了治疗癌症的方法，包括施用DLL4拮抗剂和一种或多种抗高血压药。 还描述了包含DLL4拮抗剂和一种或多种抗高血压剂的药物组合物，以及包含其的试剂盒。
-
46.发明授权Method of treating cancer using antibodies to a non-ligand binding region of NOTCH1 有权使用NOTCH1非配体结合区域的抗体治疗癌症的方法公开(公告)号：US08784811B2
公开(公告)日：2014-07-22
申请号：US13773921
申请日：2013-02-22
发明人： John A. Lewicki , Austin Gurney , Timothy Hoey , Wan-ching Yen , Sanjeev Satyal
IPC分类号： A61K39/395 , C07K16/18 , C07K16/28
CPC分类号： C07K16/30 , A61K39/39558 , A61K45/06 , A61K2039/505 , A61K2039/507 , A61N5/10 , C07K16/18 , C07K16/28 , C07K16/3015 , C07K16/3046 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/34 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/76 , C07K2317/92
摘要： The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human NOTCH receptor and inhibits growth of tumor cells. The present invention further provides a method of treating cancer, the method comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human NOTCH receptor protein and inhibits growth of tumor cells.
摘要翻译： 本发明涉及用于表征，诊断和治疗癌症的组合物和方法。 特别地，本发明提供了用于癌症的诊断，表征，预后和治疗以及特异性靶向癌症干细胞的方法和方法。 本发明提供了特异性结合人类NOTCH受体的细胞外结构域的非配体结合区并抑制肿瘤细胞生长的抗体。 本发明还提供了一种治疗癌症的方法，所述方法包括施用治疗有效量的特异性结合人NOTCH受体蛋白的细胞外结构域的非配体结合区的抗体并抑制肿瘤细胞的生长。
-
公开(公告)号：US20140065149A1
公开(公告)日：2014-03-06
申请号：US14020567
申请日：2013-09-06
发明人： Timothy C. HOEY , Lucia Beviglia
IPC分类号： A61K39/395 , A61K47/48 , C12Q1/68 , A61K45/06
CPC分类号： A61K39/3955 , A61K39/39533 , A61K39/39558 , A61K45/06 , A61K2039/505 , A61K2039/507 , C07K16/22 , C07K16/24 , C07K16/28 , C07K16/30 , C07K2317/34 , C07K2317/565 , C07K2317/76 , C12Q1/6886 , A61K2300/00
摘要： Methods of inhibiting melanoma tumor growth, methods of treating melanoma and metastatic melanoma, and methods of reducing the frequency of tumor initiating cells (or cancer stem cells) in melanoma tumors are described. The methods described comprise administering a DLL4 antagonist (e.g., an antibody that specifically binds the extracellular domain of human DLL4) to a subject. Related polypeptides and polynucleotides, compositions comprising the DLL4 antagonists, and methods of making the DLL4 antagonists are also described.
摘要翻译： 描述了抑制黑素瘤肿瘤生长的方法，治疗黑素瘤和转移性黑素瘤的方法，以及降低黑素瘤肿瘤中肿瘤起始细胞（或癌干细胞）频率的方法。 所述方法包括向受试者施用DLL4拮抗剂（例如，特异性结合人DLL4的细胞外结构域的抗体）。 还描述了相关多肽和多核苷酸，包含DLL4拮抗剂的组合物，以及制备DLL4拮抗剂的方法。
-
公开(公告)号：US08628774B2
公开(公告)日：2014-01-14
申请号：US13408704
申请日：2012-02-29
申请人： Austin Gurney , Aaron K. Sato
发明人： Austin Gurney , Aaron K. Sato
IPC分类号： A61K39/395
CPC分类号： A61K39/39558 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K14/723 , C07K16/18 , C07K16/28 , C07K16/30 , C07K2317/14 , C07K2317/21 , C07K2317/24 , C07K2317/76 , C07K2319/30
摘要： The present invention relates to compositions and methods for characterizing, diagnosing and treating cancer. In particular, the present invention identifies LGR5 as a protein over-expressed in solid tumor stem cell. The present invention further identifies an interaction between RSPO1 and LGR5 as an alternative pathway for the activation of beta-catenin signaling. In certain embodiments, the present invention provides biomolecules that disrupt functional signaling via a LGR protein, including, in certain embodiments, molecules that inhibit the interaction between one or more RSPO proteins and one or more LGR proteins, such as LGR5. In certain embodiments, the present invention provides methods of treating cancer comprising disrupting functional LGR signaling and inhibiting growth of a solid tumor comprising solid tumor stem cells.
摘要翻译： 本发明涉及用于表征，诊断和治疗癌症的组合物和方法。 特别地，本发明将LGR5鉴定为在实体瘤干细胞中过表达的蛋白质。 本发明进一步鉴定了RSPO1和LGR5之间的相互作用，作为β-连环蛋白信号传导活化的替代途径。 在某些实施方案中，本发明提供了通过LGR蛋白破坏功能性信号传导的生物分子，包括在某些实施方案中抑制一种或多种RSPO蛋白与一种或多种LGR蛋白如LGR5之间相互作用的分子。 在某些实施方案中，本发明提供了治疗癌症的方法，包括破坏功能性LGR信号并抑制包含固体肿瘤干细胞的实体瘤的生长。
-
公开(公告)号：US20140005076A1
公开(公告)日：2014-01-02
申请号：US14020012
申请日：2013-09-06
IPC分类号： C12N15/10
CPC分类号： C07K14/70514 , C07K16/00 , C07K16/22 , C07K16/28 , C07K16/2851 , C07K16/2863 , C07K2317/34 , C07K2317/52 , C07K2317/64 , C07K2319/035 , C07K2319/30 , C07K2319/43 , C07K2319/60 , C12N15/1037 , G01N33/6845 , G01N33/6854
摘要： The invention relates to novel polypeptides and cells comprising the polypeptides. The polypeptides and cells are used in methods to identify and/or isolate cells producing a protein with specific biological functions. In particular, the methods may be used for identifying, selecting, and isolating cells producing antigen-specific monoclonal antibodies.
摘要翻译： 本发明涉及包含多肽的新型多肽和细胞。 多肽和细胞用于鉴定和/或分离产生具有特定生物学功能的蛋白质的细胞。 特别地，所述方法可用于鉴定，选择和分离产生抗原特异性单克隆抗体的细胞。
-
公开(公告)号：US20130323265A1
公开(公告)日：2013-12-05
申请号：US13885249
申请日：2011-11-15
IPC分类号： A61K39/395 , A61K45/06
CPC分类号： A61K39/3955 , A61K31/337 , A61K31/7068 , A61K45/06 , A61K2039/505 , A61K2039/545 , C07K16/22 , C07K2317/565
摘要： The present invention provides methods for treating cancer. More particularly, the invention provides methods for treating cancer comprising administrating doses of a DLL4 antagonist.
摘要翻译： 本发明提供了治疗癌症的方法。 更具体地，本发明提供了治疗癌症的方法，包括施用剂量的DLL4拮抗剂。
-
-
-
-
-
-
-
-
-
搜索结果
179 条记录 (耗时 0.058 秒)
